Protection against Swine Erysipelas (SE) and Porcine Parvovirus (PPV) mainly comes from humoral immunity induced by consecutive vaccinations. Therefore, when a serological analysis is performed by means of a serological profile in a herd of vaccinated
breeders, it is expected that most of the sows will be seropositive. If seronegative sows are detected in the herd, these sows represent sub-populations exposed to diseases if they come into contact with the reproductive pathogens during the gestation period1-3.
ERYSENG® PARVO is a new bivalent vaccine against SE and PPV, adjuvanted with HIPRAMUNE® Gd. The aim of this study was to compare the humoral immune response to SE and PPV developed by two commercial vaccines, ERYSENG® PARVO and Vaccine A (vaccine against SE, PPV and Leptospira, adjuvanted with Amphigen®).